GlobeNewswire

35 New Strategic Partnerships Fueling Comodo CA's Booming Channel Growth

Dela

45 percent year over year growth

CLIFTON, N.J., March 13, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, today announced the addition of 35 new strategic partnerships, positioning its channel program for another record year in 2018.  The new partner relationships come amid continued momentum Comodo CA is seeing across its business. New partners include:  
Wix.com, Secure128, AdwebTech, DonDominio , and GeoCerts.

"The record-setting growth we've seen in the last year is testament to the clear value partners are experiencing with our partner program," said Michael Fowler, Comodo CA President of Channels.  "Since 2001 we've been the leader in helping partners succeed, breaking new ground in building and executing a best-in-class channel program.  These new strategic partners have been exclusive to our competitors for more than a decade and are globally diverse, some are the largest providers within their specific regions. This momentum is of course assisting our expansion within these net- new verticals and geographies, and we are delighted to be part of their success."

To support the rapidly growing channel momentum, Comodo CA has made significant enhancements to its global Channel Partner Program.  Over the past year it has bolstered its executive team with industry veterans, built up its sales and marketing teams, and improved pre- and post-support functions globally. Additionally, channel partners are being rewarded with new financial incentives such as the Annual Growth Rebate Program, increased revenue opportunities for partners with enterprise solutions, pre-qualified leads, free competitor replacement program and Marketing Development Funds (MDF). These new strategic partners are coming to Comodo CA for differentiated value.

Quotes from newly signed partners:

"Comodo CA's infrastructure and technical capabilities help us to deploy and manage security for our customers at scale. We needed a solution that could handle volume, as well as provide dedicated service and support. This partnership provides a valuable layer of security features for our customers as part of their Wix website service." - Dror Shaked, SVP of Business Development at  Wix

"Comodo CA's product offerings will help Adwebtech expand our portfolio of cybersecurity solutions, adding to our SSL, digital signatures and managed public key infrastructure offerings.  With the growing global onslaught of cybercrime, our customers are eager to improve their digital security to avoid business and financial harm. Comodo CA's solutions will help us deliver even greater value to our customers." - Apurva Mody, CEO at  Adwebtech

"We choose Comodo CA for their suite of innovative solutions that easily integrate into our core offering.  What makes the partnership so successful is the support and 1:1 attention we are seeing from everyone across the organization.  They are all dedicated to our success."  -  Anthony Capodicasa, CEO of Secure128

"We pride ourselves on providing customers with market-leading solutions at a fair price, followed up by outstanding customer support; the partnership with Comodo CA is a strong contributor to that mission.  Comodo CA's partner-first approach and ability to bring new, innovative security solutions to market make the company an ideal partner for us." - Scott Rogers CEO of  GeoCerts

"Comodo CA is the perfect cybersecurity partner for us. We can now provide market-leading security solutions to our end users and resellers with the support of the number 1 online trust provider."  - Marc Gelabert, CRO of  DonDominio

To learn more about the Comodo CA partner program visit https://www.comodoca.com/partners, or contact our channel partner team at partners@comodoca.com.

About Comodo CA
A trusted advisor by enterprises globally for more than two decades, Comodo CA provides digital identity solutions for businesses of all sizes - protecting their employees, customers, intellectual property and overall brand - from damages caused by fraudsters impersonating people and devices.  
As the largest commercial certificate authority with over 100 million SSL certificates issued worldwide, Comodo CA has the experience and performance to meet the growing need to secure transactions and create online trust. For more information, visit ComodoCA.com or via twitter @Comodo_SSL.

 

Contact:
Lisa Johnson
lisa@ljstratcomm.com
425-766-8736



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Comodo CA via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum